Protein inhibitors to complement and VEGF pathways and methods of use thereof

A method of treating a subject with a) a solid tumor associated with angiogenesis or b) an ocular disease or condition associated with abnormal blood vessel in an eye, comprising administering to the subject an effective amount of a fusion protein, wherein the fusion protein comprises, from the N-terminal to C-terminal, a VEGF inhibiting domain (VID), an immunoglobulin Fc region, and a complement inhibiting domain (CID), wherein the fusion protein inhibits complement activation and VEGF activity, wherein the CID comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:1-4, and wherein the VID comprises the amino acid sequence of SEQ ID NO:11 or 38.

A method of treating a subject with a) a solid tumor associated with angiogenesis or b) an ocular disease or condition associated with abnormal blood vessel in an eye, comprising administering to the subject an effective amount of a fusion protein, wherein the fusion protein is produced by culturing a host cell comprising a nucleic acid encoding a fusion protein comprising the amino acid sequence of SEQ ID NO:12 or 40 under a condition that produces the fusion protein, and recovering the fusion protein produced by the host cell.